Welcome to the UPF Digital Repository

Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study

Show simple item record

dc.contributor.author Ranzani, Otavio
dc.contributor.author Silva, Amanda A. B.
dc.contributor.author Peres, Igor T.
dc.contributor.author Antunes, Bianca B. P.
dc.contributor.author Gonzaga-da-Silva, Thiago W.
dc.contributor.author Soranz, Daniel R.
dc.contributor.author Cerbino-Neto, José
dc.contributor.author Hamacher, Silvio
dc.contributor.author Bozza, Fernando A.
dc.date.accessioned 2022-05-02T06:08:41Z
dc.date.available 2022-05-02T06:08:41Z
dc.date.issued 2022
dc.identifier.citation Ranzani OT, Silva AAB, Peres IT, Antunes BBP, Gonzaga-da-Silva TW, Soranz DR, Cerbino-Neto J, Hamacher S, Bozza FA. Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study. Clin Microbiol Infect. 2022 Feb 9;28(5):736.e1-4. DOI: 10.1016/j.cmi.2022.01.032
dc.identifier.issn 1198-743X
dc.identifier.uri http://hdl.handle.net/10230/52952
dc.description.abstract Objectives: To estimate vaccine effectiveness after the first and second dose of ChAdOx1 nCoV-19 against symptomatic COVID-19 and infection in a socially vulnerable community in Brazil when Gamma and Delta were the predominant variants circulating. Methods: We conducted a test-negative study in the community Complexo da Maré, the largest group of slums (n = 16) in Rio de Janeiro, Brazil, from January 17, 2021 to November 27, 2021. We selected RT-qPCR positive and negative tests from a broad community testing program. The primary outcome was symptomatic COVID-19 (positive RT-qPCR test with at least one symptom) and the secondary outcome was infection (any positive RT-qPCR test). Vaccine effectiveness was estimated as 1 - OR, which was obtained from adjusted logistic regression models. Results: We included 10 077 RT-qPCR tests (6,394, 64% from symptomatic and 3,683, 36% from asymptomatic individuals). The mean age was 40 (SD: 14) years, and the median time between vaccination and RT-qPCR testing among vaccinated was 41 (25-75 percentile: 21-62) days for the first dose and 36 (25-75 percentile: 17-59) days for the second dose. Adjusted vaccine effectiveness against symptomatic COVID-19 was 31.6% (95% CI, 12.0-46.8) 21 days after the first dose and 65.1% (95% CI, 40.9-79.4) 14 days after the second dose. Adjusted vaccine effectiveness against COVID-19 infection was 31.0% (95% CI, 12.7-45.5) 21 days after the first dose and 59.0% (95% CI, 33.1-74.8) 14 days after the second dose. Discussion: ChAdOx1 nCoV-19 was effective in reducing symptomatic COVID-19 in a socially vulnerable community in Brazil when Gamma and Delta were the predominant variants circulating.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartof Clin Microbiol Infect. 2022 Feb 9;28(5):736.e1-4
dc.rights © 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1016/j.cmi.2022.01.032
dc.subject.keyword Brazil
dc.subject.keyword COVID-19
dc.subject.keyword Test-negative
dc.subject.keyword Vaccine
dc.subject.keyword Vulnerable community
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking